Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: Urinary exosomal hemopexin was identified as a potential diagnostic candidate for kidney allograft rejection in our previous proteomic study. We validated hemopexin as a predictor of acute T cell-mediated rejection (TCMR) as well as chronic active antibody-mediated rejection (CAMR).
*Methods: Urine samples from kidney transplant recipients (KTRs) who underwent graft biopsy were analyzed. There were 98 graft biopsies and we compared the KTRs with stable graft function (STA), TCMR, and CAMR groups. Each patient’s urinary exosome was isolated by exosome isolation kit, and urinary exosomal hemopexin level was measured by ELISA method. To evaluate the discrimination ability, receiver operating characteristic (ROC) analysis was applied.
*Results: Nineteen patients were classified as STA, 18 were TCMR, and 11 were CAMR. The median urinary exosomal hemopexin level was 5.47 (interquartile, 4.30−10.22) ng/mL in STA, 66.87 (28.70−137.95) ng/mL in TCMR, and 162.07 (101.96−221.30) ng/mL in CAMR. Both TCMR and CAMR groups showed significantly higher levels of hemopexin compared to STA group (both P<0.001). In ROC analysis, urinary exosomal hemopexin in TCMR showed an area under curve of 0.90 (95% CI 0.78−1.00) and 0.95 (0.86−1.00) in CAMR.
*Conclusions: Urinary exosomal hemopexin levels were increased in TCMR and CAMR. It could be a potential diagnostic marker for both TCMR and CAMR.
To cite this abstract in AMA style:Lee J, Kim J, Lee G, Jeon S, Noh H, Lim J, Jung H, Choi J, Cho J, Park S, Kim Y, Kim C. Urinary Exosomal Hemopexin, a Validated Diagnostic Marker for Rejection in Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/urinary-exosomal-hemopexin-a-validated-diagnostic-marker-for-rejection-in-kidney-transplant-recipients/. Accessed February 27, 2021.
« Back to 2020 American Transplant Congress